glp 1 news today FDA approves Foundayo, an oral GLP-1 alternative to Wegovy and Ozempic Eli Lilly CEO launches Medicare

Some patients experience mild nausea, bloating, or digestive discomfort during the first few weeks as the body adjusts

It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists

The number doubled in 18 months This is a recent surge

A recent meta-analysis including data from SURMOUNT-1, a trial conducted in individuals with obesity, confirmed the favorable effects of tirzepatide on dyslipidemia, finding a 16 and 13.7% change from baseline in triglycerides and very low-density lipoproteins with tirzepatide 15 mg vs

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications